Digbi Health Publishes Peer-Reviewed Data Demonstrating Significant Cost Savings for Employers Via Its Precision Biology Telehealth Platform to Manage GLP-1, Metabolic, and GI Costs

MOUNTAIN VIEW, Calif., January 15, 2026 /Digbi Newswire/ -- Digbi Health, the national leader in Precision Biology-based chronic care, today announced peer-reviewed, actuarially validated healthcare cost savings for employers. The findings of this multi-year, multi-employer medical claims analysis were published in the peer-reviewed journal Healthcare.

The analysis confirms that employers using Digbi Health's Precision Biology platform achieved actuarially guaranteed, hard-dollar reductions in medical claims, driven by lower pharmaceutical utilization and reduced inpatient and outpatient costs. These savings were achieved by treating five chronic conditions — obesity, metabolic, gastrointestinal, mental health and auto-immune — on a single platform, informed by genetic insights, gut microbiome analysis, and more than 8,000 biomarkers.

The announcement marks a milestone for an industry that has historically relied on engagement and other soft metrics while struggling to demonstrate direct medical cost reduction.

Validated cost savings by condition

The claims analysis evaluated multiple years of medical spend across seven U.S. self-insured employers, comparing Digbi Health participants with matched non-participants. The study identified significant reductions in medical claims:

• Digestive and GI cost reduction: $9,240+ per member per year
• Obesity-related medical cost reduction: $4,884+ per member per year
• Anxiety-related medical cost reduction: $1,356+ per member per year
• Overall medical spend reduction: $3,012 per member per year

Precision Biology as the new standard of care

While most high-cost claimants are polychronic, traditional digital care programs treat these conditions in silos, resulting in fragmented care, poor engagement, overlapping medications and escalating costs.

Digbi Health's Precision Biology platform targets the root cause of biological and behavioral change by analyzing biomarkers from the gut microbiome, blood and genetic tests, along with dietary intake, to treat multiple conditions simultaneously — replacing fragmented point solutions with a single coordinated system of care.

More than 300 employers and health plans are already using Digbi Health to manage 70% of their healthcare controllable costs driven by GLP-1s, obesity, metabolic, and GI conditions. Precision Biology is no longer the future of care — it is the new standard. Just as we pioneered Precision Biology in chronic care, we are now showing leadership in proving that root-cause treatment can materially reduce medical claims across multiple conditions and clean up the point solutions proliferation.

— Ranjan Sinha, Founder and CEO, Digbi Health

Extending savings in the GLP era

Digbi Health continues to expand its GLP-1 offering to include direct-to-employer and employee cash-pay fulfillment options, while supporting PBM and 340B medication access.

By combining GLP-1 therapy with biologically personalized support, Digbi Health achieves significant reductions in GLP-1 adverse effects, improving adherence and weight loss outcomes and further extending the medical savings demonstrated in the claims analysis.

Originally distributed via GLOBE NEWSWIRE.